All In Biotech

Drug Trial Radar · NCT05052567

CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1b/2 Clinical Study on Safety, Pharmacokinetics, and Preliminary Efficacy of CEND-1 for Injection in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Oct 21, 2021

Primary completion

Jun 29, 2024

Study completion Jun 29, 2024

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Cend Therapeutics Inc.
First posted
Sep 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the preliminary safety, efficacy and PK characteristics of cend-1 in patients with advanced metastatic pancreatic ductal adenocarcinoma (Chinese population).

Conditions

  • Pancreatic Cancer

Interventions

  • CEND-1Drug

    The dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of CEND-1 mesured by AEs, SAEs and treatment related adverse events.Time frame: 12 month
  2. Preliminary efficacy of CEND-1 mesured by ORR, DOR, DCR, OS, PFS ect.Time frame: 12 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.